Discovery and Development of Sunitinib (SU11248): A Multitarget Tyrosine Kinase Inhibitor of Tumor Growth, Survival, and Angiogenesis
- 29 September 2009
- book chapter
- Published by Wiley
- p. 1-39
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profilingProceedings of the National Academy of Sciences, 2007
- Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteinsJournal of Translational Medicine, 2007
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine KinaseJournal of Medicinal Chemistry, 2003
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996
- Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endotheliumNature, 1995
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factorBiochemical and Biophysical Research Communications, 1992
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochemical and Biophysical Research Communications, 1989
- ISOLATION OF A TUMOR FACTOR RESPONSIBLE FOR ANGIOGENESISJournal of Experimental Medicine, 1971